110 related articles for article (PubMed ID: 28105615)
1. [Improvement of prognostic and predictive network of colorectal cancer based upon the 8th edition of AJCC colorectal cancer staging system].
Yao H; Wu H; Liu Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Jan; 20(1):24-27. PubMed ID: 28105615
[TBL] [Abstract][Full Text] [Related]
2. [From traditional population-based approach to individualized precision medicine: the interpretation of update on
Yao HW; Wu HW; Liu YH
Zhonghua Wai Ke Za Zhi; 2017 Jan; 55(1):24-27. PubMed ID: 28056249
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis.
Zlobec I; Bihl MP; Schwarb H; Terracciano L; Lugli A
Int J Cancer; 2010 Jul; 127(2):367-80. PubMed ID: 19908233
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological characteristics and prognostic impact of colorectal cancers with NRAS mutations.
Ogura T; Kakuta M; Yatsuoka T; Nishimura Y; Sakamoto H; Yamaguchi K; Tanabe M; Tanaka Y; Akagi K
Oncol Rep; 2014 Jul; 32(1):50-6. PubMed ID: 24806883
[TBL] [Abstract][Full Text] [Related]
5. Associations of defect mismatch repair genes with prognosis and heredity in sporadic colorectal cancer.
Ghanipour L; Jirström K; Sundström M; Glimelius B; Birgisson H
Eur J Surg Oncol; 2017 Feb; 43(2):311-321. PubMed ID: 27836416
[TBL] [Abstract][Full Text] [Related]
6. Prognostic and predictive biomarkers in nonmetastatic colorectal cancers.
Haddad FG; Eid R; Kourie HR; Barouky E; Ghosn M
Future Oncol; 2018 Sep; 14(21):2097-2102. PubMed ID: 30101612
[No Abstract] [Full Text] [Related]
7. Serrated colorectal cancer: Molecular classification, prognosis, and response to chemotherapy.
Murcia O; Juárez M; Hernández-Illán E; Egoavil C; Giner-Calabuig M; Rodríguez-Soler M; Jover R
World J Gastroenterol; 2016 Apr; 22(13):3516-30. PubMed ID: 27053844
[TBL] [Abstract][Full Text] [Related]
8. Metastatic Pattern of Stage IV Colorectal Cancer with High-Frequency Microsatellite Instability as a Prognostic Factor.
Fujiyoshi K; Yamamoto G; Takenoya T; Takahashi A; Arai Y; Yamada M; Kakuta M; Yamaguchi K; Akagi Y; Nishimura Y; Sakamoto H; Akagi K
Anticancer Res; 2017 Jan; 37(1):239-247. PubMed ID: 28011498
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers.
de Cuba EM; Snaebjornsson P; Heideman DA; van Grieken NC; Bosch LJ; Fijneman RJ; Belt E; Bril H; Stockmann HB; Hooijberg E; Punt CJ; Koopman M; Nagtegaal ID; Coupé VH; Carvalho B; Meijer GA
Int J Cancer; 2016 Mar; 138(5):1139-45. PubMed ID: 26376292
[TBL] [Abstract][Full Text] [Related]
10. Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability.
Umeda Y; Nagasaka T; Mori Y; Sadamori H; Sun DS; Shinoura S; Yoshida R; Satoh D; Nobuoka D; Utsumi M; Yoshida K; Yagi T; Fujiwara T
J Hepatobiliary Pancreat Sci; 2013 Feb; 20(2):223-33. PubMed ID: 23010994
[TBL] [Abstract][Full Text] [Related]
11. Prognostic and Predictive Biomarkers in Colorectal Cancer: Implications for the Clinical Surgeon.
Erstad DJ; Tumusiime G; Cusack JC
Ann Surg Oncol; 2015 Oct; 22(11):3433-50. PubMed ID: 26215192
[TBL] [Abstract][Full Text] [Related]
12. High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort.
Sorbye H; Dragomir A; Sundström M; Pfeiffer P; Thunberg U; Bergfors M; Aasebø K; Eide GE; Ponten F; Qvortrup C; Glimelius B
PLoS One; 2015; 10(6):e0131046. PubMed ID: 26121270
[TBL] [Abstract][Full Text] [Related]
13. Combined mutational analysis of KRAS, NRAS and BRAF genes in Indian patients with colorectal carcinoma.
Bagadi SB; Sanghvi M; Nair SB; Das BR
Int J Biol Markers; 2012; 27(1):27-33. PubMed ID: 22427190
[TBL] [Abstract][Full Text] [Related]
14. Molecular Biomarkers in the Personalized Treatment of Colorectal Cancer.
Sinicrope FA; Okamoto K; Kasi PM; Kawakami H
Clin Gastroenterol Hepatol; 2016 May; 14(5):651-8. PubMed ID: 26872400
[TBL] [Abstract][Full Text] [Related]
15. [Biomarker for colorectal cancer].
Nagasaka T; Mori Y; Umeda Y; Fujiwara T
Nihon Rinsho; 2012 May; 70(5):802-8. PubMed ID: 22620004
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence.
Tsilimigras DI; Ntanasis-Stathopoulos I; Bagante F; Moris D; Cloyd J; Spartalis E; Pawlik TM
Surg Oncol; 2018 Jun; 27(2):280-288. PubMed ID: 29937183
[TBL] [Abstract][Full Text] [Related]
17. High concordance rate of KRAS/BRAF mutations and MSI-H between primary colorectal cancer and corresponding metastases.
Fujiyoshi K; Yamamoto G; Takahashi A; Arai Y; Yamada M; Kakuta M; Yamaguchi K; Akagi Y; Nishimura Y; Sakamoto H; Akagi K
Oncol Rep; 2017 Feb; 37(2):785-792. PubMed ID: 28000889
[TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study.
Palomba G; Doneddu V; Cossu A; Paliogiannis P; Manca A; Casula M; Colombino M; Lanzillo A; Defraia E; Pazzola A; Sanna G; Putzu C; Ortu S; Scartozzi M; Ionta MT; Baldino G; Sarobba G; Capelli F; Sedda T; Virdis L; Barca M; Gramignano G; Budroni M; Tanda F; Palmieri G
J Transl Med; 2016 Oct; 14(1):292. PubMed ID: 27737711
[TBL] [Abstract][Full Text] [Related]
19. The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients.
Won DD; Lee JI; Lee IK; Oh ST; Jung ES; Lee SH
BMC Cancer; 2017 Jun; 17(1):403. PubMed ID: 28583095
[TBL] [Abstract][Full Text] [Related]
20. High MACC1 expression in combination with mutated KRAS G13 indicates poor survival of colorectal cancer patients.
Ilm K; Kemmner W; Osterland M; Burock S; Koch G; Herrmann P; Schlag PM; Stein U
Mol Cancer; 2015 Feb; 14():38. PubMed ID: 25742883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
